A specific inhibitor of PTEN
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VO-OHpic (hydrate)

Item No. 10009965

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(OC-6-45)-aqua(3-hydroxy-2-pyridinecarboxylato-κN1,κO2)[3-(hydroxy-κO)-2-pyridinecarboxylato(2-)-κO2]oxo-vanadate(1-), hydrogen, trihydrate
CAS Number
476310-60-8
Molecular Formula
C12H9N2O8V • H [3H2O]
Formula Weight
415.2
Purity
≥95%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 1 mg/ml
λmax
303 nm
SMILES
[OH2][V+2]([N]1=CC=CC(O)=C1C2=O)([O-]C3=CC=CN=C3C4=O)([O-]2)([O-]4)=O.O.O.O.[H+]
InChi Code
InChI=1S/2C6H5NO3.4H2O.O.V/c2*8-4-2-1-3-7-5(4)6(9)10;;;;;;/h2*1-3,8H,(H,9,10);4*1H2;;/q;;;;;;;+2/p-2
InChi Key
RFJZXRRNSIRYLW-UHFFFAOYSA-L
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $37

    Add

    5 mg

    $106

    Add

    10 mg

    $158

    Add

    25 mg

    $349

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    VO-OHpic is a specific inhibitor of phosphatase and tensin homolog (PTEN; IC50 = 35 nM in vitro).1,2 Through this action, it increases cellular phosphatidylinositol 3,4,5-trisphosphate (PIP3) levels, phosphorylation of Akt, and glucose uptake in adipocytes.1 In mice, VO-OHpic (10 µg/kg, i.p.) decreases left ventricular systolic pressure and heart rate and protects against ischemia/reperfusion-induced myocardial infarction.3 VO-OHpic also blocks the development of suppressor activity in regulatory T cells activated with indoleamine 2,3-dioxygenase.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Rosivatz, E., Matthews, J.G., McDonald, N.Q., et al. A small-molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem. Biol. 1(12), 780-790 (2006).

    2. Mak, L.H., Vilar, R., and Woscholski, R. Characterisation of the PTEN inhibitor VO-OHpic. J. Chem. Biol. 3(4), 157-163 (2010).

    3. Zu, L., Shen, Z., Wesley, J., et al. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur. J. Pharmacol. 650(1), 298-302 (2011).

    4. Sharma, M.D., Shinde, R., McGaha, T.L., et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci. Adv. 1(10), e1500845 (2015).